Research & Regulatory News

Retatrutide Expanded Access: What It Actually Is

UKPWritten and published by UK Peptides2 min readUpdated 3 cited sources

The short answer

ClinicalTrials.gov lists a pre-approval expanded access record for retatrutide (NCT07629401) with a status of available. Expanded access is a regulated route by which a sponsor may supply an unapproved medicine to specific patients outside a trial, through their physician. It is not a purchase route and not a general availability signal.

Key facts

Registration
NCT07629401
Type
Pre-approval expanded access
Status
Available
Sponsor
Eli Lilly and Company
Not a
Clinical trial (no phase, no endpoints)
Access route
Through a treating physician to the sponsor
Regulatory status
Retatrutide remains unapproved

What expanded access is

Expanded access, sometimes called compassionate use, is a regulated pathway allowing a patient with a serious condition to receive an investigational medicine outside a clinical trial. It requires a treating physician to request it, the sponsor to agree to supply, and regulatory and ethics oversight. It exists for patients who cannot enrol in a trial and have no satisfactory alternative.

Why it appears on a trials registry at all

ClinicalTrials.gov records expanded access programmes alongside trials, but they are a different kind of record, no phase, no enrolment target, no primary outcome measure, because nothing is being measured. The status field reads available rather than recruiting. Seeing it in a search for retatrutide trials and reading it as another study is an easy mistake.

Research material referenced

Retatrutide 10mg, third-party HPLC tested

Buy Retatrutide · £59.99

What it does not mean

It does not mean retatrutide is approved, approaching approval, or generally obtainable. It does not create a supply route for anyone outside the defined pathway, and it is not something an individual can apply to directly. The compound remains investigational in every jurisdiction, and its regulatory status is unchanged by the existence of this record.

Why it still matters

Expanded access records get cited in discussion as evidence that a compound is becoming available. It is a reasonable-sounding inference and it is wrong. The programme is a narrow clinical mechanism operating under sponsor and regulator control, and conflating it with availability is the sort of error that propagates quickly once someone makes it.

The distinction that matters here

Material supplied for laboratory research is not connected to this programme in any way. It is not the same supply, not an alternative to it, and not a route into it. Research material is supplied for laboratory use only, and nothing about an expanded access listing changes that.

Frequently asked questions

Can I get retatrutide through expanded access?

It is not a route individuals can pursue directly. Expanded access requires a treating physician's request, sponsor agreement, and regulatory oversight, for patients meeting defined criteria.

Does an expanded access listing mean approval is close?

No. It is a separate mechanism from approval and says nothing about the timing of any regulatory decision.

Why does it show on ClinicalTrials.gov without a phase?

Because it is not a trial. Nothing is being measured, so there is no phase, enrolment target or outcome measure.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More Research & Regulatory News articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.